Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoi

KEYTRUDA® (pembrolizumab) plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients

Related Keywords

Rome , Lazio , Italy , Canada , United States , Domenica Lorusso , Gursel Aktan , Facebook , European Network For Gynaecological Oncology Trial , Foundation Inc , Exchange Commission , Catholic University Of Rome , Linkedin , Twitter , Youtube , Instagram , Statement Of Merck Co Inc , Data Monitoring Committee , Merck Co Inc , Merck Research Laboratories , Merck Research , Catholic University , European Network , Gynaecological Oncology Trial , Selected Important Safety , Important Safety Information , Fatal Immune Mediated Adverse Reactions , Single Agent , Thyroid Disorders , Which Can Present With Diabetic Ketoacidosis , Nervous System , Connective Tissue , Patients With Multiple Myeloma , Neck Squamous Cell Cancer , Bacillus Calmette Guerin Unresponsive , Mismatch Repair Deficient Cancer , Mismatch Repair Deficient Colorectal Cancer , Looking Statement , Securities Litigation Reform Act , Annual Report , Markets ,